Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expansion Study of EP-104GI

Next Previous
Search
Trial Profile

Expansion Study of EP-104GI

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 28 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluticasone propionate (Primary)
  • Indications Eosinophilic oesophagitis
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 27 May 2024 New trial record
    • 23 May 2024 According to a Eupraxia Pharmaceuticals media release, additional clinical sites will be added in current jurisdictions to support the new recruitment target, and site feasibility has commenced to open additional geographic regions as needed to support the trial expansion.
    • 23 May 2024 According to a Eupraxia Pharmaceuticals media release, the company anticipates commencing this trial in 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top